72). No relation of osteopontin levels to ultrasound hemodynamic parameters (portal vein diameter, portal vein flow, spleen size) was found. Conclusions: Osteopontin is closely related to HVPG and could be a new non-invasive marker of portal hypertension. It could also discriminate the patients with clinically significant portal hypertension. Supported by IGA MZCR NT 12290/4 and SVV 260032-2014. Disclosures: The following people have nothing to disclose: Radan INK 128 manufacturer Bruha, Marie Jachymova,

Jaromir Petrtyl, Libor Vitek, Petr Urbanek, Karel Dvorak Aims: Occlusion of portosystemic shunts (PSS) by balloon-occluded retrograde transvenous obliteration (B-RTO) is effective for the management of gastric varices (GV) and hepatic encephalopathy (HE), but it can result in severe complications, such ascites and aggravation of esophageal varices due to elevated check details portal venous pressure (PVP). The present study investigated the effect of partial splenic embolization (PSE) in addition to B-RTO on PVP and hepatic function in patients with cirrhosis. Methods: Seventeen cirrhotic patients (mean age=68.1 years; female/male=8/9; hepatitis C virus/alcohol/nonalcoholic ste-atohepatitis=8/5/4;

Child-Pugh (CP) class A/B=6/11) with GV and/or HE caused by PSS underwent both B-RTO and PSE (group B/P) separately at our hospital between November 2008 and January 2014. Patients were categorized into two groups: group P-B (9 patients; PSE first, then B-RTO) and group B-P (8 patients; 上海皓元医药股份有限公司 B-RTO first, then PSE). Testing was performed before the first procedure and at 3 months after the second procedure, and the data were retrospectively compared with those of 28 patients who underwent B-RTO alone (group B). Results: There were no significant

differences in preoperative characteristics, such as gender, age, etiology, CP class, and indication for procedure, between group B/P and group B. Both combined therapy and B-RTO monotherapy resulted in improved liver function parameters, including total bilirubin, albumin, cholinesterase, and prothrombin activity, and CP score (points) was decreased to a greater degree in group B/P than in group B [7.0 to 5.9 (p<0.01) vs. 6.5 to 6.0 (p<0.05)], indicating a synergistic effect of PSE in combination with B-RTO on hepatic function. While B-RTO alone led to a significant increase in wedged hepatic venous pressure [wHVP, mmH2O; 248.1 to 305.6 (p<0.01)] and hepatic venous pressure gradient [HVPG, mmH2O; 142.2 to 176.4 (p<0.01)], PSE inhibited the elevation of PVP after occlusion of PSS (wHVP, 208.3 to 213.3; HVPG, 120.0 to 100.0). Consequently, the incidence of complications was significantly lower in group B/P than in group B (5.9% vs. 39.3%, p<0.05). Furthermore, when comparing group P-B and group B-P, changes in CP score/wHVP/ HVPG were 6.9 to 6.3/243.8 to 287.5/127.5 to 138.8 and 7.1 to 5.4 (p<0.01)/243.8 to 228.8/161.3 to 113.8, and the incidence of complications was 11.